In May 2016 , it was approved by the FDA for bladder cancer treatment. .
In May 2017 it failed phase 3 trial for second line bladder cancer .
In May 2016 , it was approved by the FDA for bladder cancer treatment. , but in May 2017 it failed phase 3 trial for second line bladder cancer .